

HR 6958

Drug Price Transparency Act

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 27, 2018

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 10, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/6958>

Sponsor

Name: Rep. Rooney, Francis [R-FL-19]

Party: Republican • State: FL • Chamber: House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Welch, Peter [D-VT-At Large]	D · VT		Sep 27, 2018

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 27, 2018
Ways and Means Committee	House	Referred to	Oct 10, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 27, 2018)

Drug Price Transparency Act

This bill requires the Centers for Medicare & Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development).

Actions Timeline

- **Oct 10, 2018:** Referred to the Subcommittee on Health.
- **Sep 27, 2018:** Introduced in House
- **Sep 27, 2018:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.